In mouse and human melanoma, a triple-positive (CXCR3+CCR5+CXCR6+) T-cell subset is essential for tumor control, and its genetic signature correlates with positive clinical response, while a distinct CCR5+CXCR6+ subset drives liver immune-related adverse events (IRAEs). Here, CXCR3 is linked to neoplasm.